CAS 1234015-54-3

Fórmula: C18H21Cl2N7O2

InChI: InChI=1S/C18H19N7O2.2ClH/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17;;/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25);2*1H

Clave InChI: KMEIPKXRCJTZBZ-UHFFFAOYSA-N

SMILES: COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N.Cl.Cl

Prexasertib dihydrochloride

CAS: 1234015-54-3

Prexasertib dihydrochloride

Fórmula: C₁₈H₂₁Cl₂N₇O₂

Pureza: 99.5%

Peso molecular: 438.31

Ref: 54-BUP12915

Prexasertib 2HCl

CAS: 1234015-54-3

5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile dihydrochloride

Fórmula: C₁₈H₂₁Cl₂N₇O₂

Pureza: 98%

Peso molecular: 438.31

Ref: IN-DG630032

Prexasertib dihydrochloride

CAS: 1234015-54-3

Prexasertib dihydrochloride (LY2606368) inhibits CHK1 (Ki: 0.9 nM); IC50: CHK2 8 nM, RSK 9 nM.

Fórmula: C₁₈H₂₁Cl₂N₇O₂

Pureza: 98.46% - 99.82%

Forma y color: Solid

Peso molecular: 438.311

Ref: TM-T4327

Prexasertib HCl (LY2606368)

CAS: 1234015-54-3

LY2606368 is a monoclonal antibody that binds to the death protein and prevents it from activating other proteins that promote cell growth. It has been shown to be effective in treating pediatric patients with metastatic pancreatic cancer. LY2606368 is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is associated with tumorigenesis. Prexasertib has been shown to induce cell lysis and apoptosis by inhibiting the Bcl-2 family of proteins, which regulate mitochondrial membrane permeability. This drug also inhibits phosphatidylinositol 3-kinases (PI3Ks) and cyclooxygenases, which are involved in tumorigenesis.

Fórmula: C₁₈H₁₉N₇O₂·2HCl

Pureza: Min. 95%

Peso molecular: 438.31 g/mol

Ref: 3D-JZB01554

5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride

CAS: 1234015-54-3

Fórmula: C₁₈H₂₁Cl₂N₇O₂

Pureza: 98%

Forma y color: Solid

Peso molecular: 438.3110

Ref: IN-DA009CIX